Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
41,419,893
-
Share change
-
+19,928,081
-
Total reported value
-
$209,166,921
-
Put/Call ratio
-
18%
-
Price per share
-
$5.05
-
Number of holders
-
69
-
Value change
-
+$105,446,084
-
Number of buys
-
42
-
Number of sells
-
25
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2023
As of 30 Jun 2023,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,419,893 shares.
The largest 10 holders included
Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., Artal Group S.A., Boxer Capital, LLC, Point72 Asset Management, L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RTW INVESTMENTS, LP, BlackRock Inc., and VANGUARD GROUP INC.
This page lists
69
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.